Low-volume insulin degludec 200 Units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The begin low volume trial

Diabetes Care

Volumn 36, Issue 9, 2013, Pages 2536-2542

  Gough, Stephen C L ^a   Bhargava, Anuj ^b   Jain, Rajeev ^c   Mersebach, Henriette ^d   Rasmussen, SØren ^d   Bergenstal, Richard M ^e  

^a NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^b Iowa Diabetes and Endocrinology Center   (United States)

^c Advanced Healthcare   (United States)

^d NOVO NORDISK A S   (Denmark)

^e INTERNATIONAL DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DEGLUDEC; INSULIN GLARGINE; METFORMIN;

ADULT; ADVERSE OUTCOME; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84889648892     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2329     Document Type: Article

References (19)

1. Obesity Society. Your weight and diabetes, 2010 [article online]. Available from: http://www.obesity.org/resourcesfor/ your-weight-and-diabetes. htm. Accessed 9 February 2012
2. Rodbard H, Handelsman Y, Gough S, Dykiel P, Lassota N, Lane W. Reduced risk of hypoglycemia with insulin degludec vs insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: meta-analysis of five randomized trials (abstract 241). Presented at the AACE 21st Annual Scientific and Clinical Congress, 23-27 May 2012, Philadelphia, Pennsylvania
3. Lane WS, Cochran EK, Jackson JA, et al. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract 2009;15: 71-79
4. Crasto W, Jarvis J, Hackett E, et al. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgrad Med J 2009; 85: 219-222
5. Heise T, Hövelmann U, Nosek L, Bøttcher SG, Granhall C, Haahr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine (Abstract). Diabetes 2011;60(Suppl. 1):LB11
6. Nosek L, Heise T, Bøttcher SG, Hastrup H, Haahr H.Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect (Abstract). Diabetes 2011;60(Suppl. 1): LB14
7. Korsatko S, Deller S, Zahiragic S, Mader J, Neubauer K, Adrian C, Thomsen H, Haahr H, Pieber T. Ultra-long-acting insulin degludec: two different formulations (U100 and U200) are bioequivalent and show similar pharmacodynamics (Abstract). Diabetes 2011;60(Suppl. 1):A624
8. Zinman B, Philis-Tsimikas A, Cariou B, et al.; NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012;35: 2464-2471
9. Heller S, Buse J, Fisher M, et al. 1 Trial Investigators. Insulin degludec, an ultralongacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379: 1489-1497
10. Garber AJ, King AB, Del Prato S, et al.; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultralongacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379: 1498-1507
11. WorldMedical Association Inc. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc 2009;107: 403-405
12. ICH harmonised tripartite guideline: guideline for good clinical practice. J Postgrad Med 2001;47: 199-203
13. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28: 1245-1249
14. Cryer PE. Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention. Alexandria, VA, American Diabetes Association, 2009
15. Unger J. Uncovering undetected hypoglycemic events. Diabetes Metab Syndr Obes 2012;5: 57-74
16. Marcus A. Diabetes caredinsulin delivery in a changing world. Medscape J Med 2008;10:120
17. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012;29: 682-689
18. Rubin RR, Peyrot M, Kruger DF, Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ 2009;35: 1014-1022
19. Garg R, Johnston V, McNally PG, Davies MJ, Lawrence IG. U-500 insulin: why, when and how to use in clinical practice. Diabetes Metab Res Rev 2007;23: 265-268